Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sanofi-Aventis Sa (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 120,273,568
  • Shares Outstanding, K 2,520,930
  • Annual Sales, $ 38,408 M
  • Annual Income, $ 4,864 M
  • 36-Month Beta 0.89
  • Price/Sales 3.24
  • Price/Cash Flow 10.41
  • Price/Book 1.91

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.79 +2.71%
on 07/19/17
49.87 -3.63%
on 06/26/17
-1.27 (-2.57%)
since 06/23/17
3-Month
46.29 +3.82%
on 04/26/17
50.24 -4.34%
on 05/16/17
+1.66 (+3.58%)
since 04/25/17
52-Week
36.81 +30.56%
on 10/26/16
50.24 -4.34%
on 05/16/17
+5.92 (+14.05%)
since 07/25/16

Most Recent Stories

More News
Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed

Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares....

LLY : 81.32 (-4.04%)
INCY : 133.89 (-3.17%)
SNY : 48.06 (+0.73%)
BIIB : 284.25 (-0.16%)
Featured Company News - Regeneron and Sanofi Receive Positive CHMP's Opinion for Dupixent(R)

MAIN, GERMANY / ACCESSWIRE / July 24, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), following which...

REGN : 512.76 (-1.62%)
SNY : 48.06 (+0.73%)
Merck's Biosimilar Insulin Gets Tentative FDA Approval

Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

MRK : 62.31 (-0.42%)
LLY : 81.32 (-4.04%)
PFE : 33.21 (-0.33%)
SNY : 48.06 (+0.73%)
Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

AZN : 33.69 (-0.47%)
JNJ : 131.79 (-0.92%)
MRK : 62.31 (-0.42%)
LLY : 81.32 (-4.04%)
NVS : 84.01 (-0.33%)
SNY : 48.06 (+0.73%)
BMY : 56.02 (+0.76%)
Sanofi Receives CHMP Positive Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis

GUILDFORD, England, July 21, 2017 /PRNewswire/ --

SNY : 48.06 (+0.73%)
Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies....

ENZ : 11.29 (-0.09%)
SRPT : 42.39 (-3.55%)
BMRN : 88.64 (-1.52%)
SNY : 48.06 (+0.73%)
Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt

Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.

ENZ : 11.29 (-0.09%)
EXEL : 27.55 (-1.99%)
VRX : 17.87 (+1.88%)
SNY : 48.06 (+0.73%)
Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

NVO : 42.13 (+0.55%)
LLY : 81.32 (-4.04%)
PFE : 33.21 (-0.33%)
SNY : 48.06 (+0.73%)
Perrigo Company Gets FDA Approval for Generic Topical Gel

Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.

ENZ : 11.29 (-0.09%)
ABBV : 72.73 (-1.60%)
SNY : 48.06 (+0.73%)
PRGO : 76.01 (-0.45%)
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

AZN : 33.69 (-0.47%)
TEVA : 32.73 (+0.80%)
RHHBY : 31.8900 (-0.81%)
SNY : 48.06 (+0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Support & Resistance

2nd Resistance Point 48.03
1st Resistance Point 47.87
Last Price 48.06
1st Support Level 47.53
2nd Support Level 47.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.